Classification and Treatment of Diseases in the Age of Genome Medicine Based on Pathway Pathology

Abstract

The focus of pathology as a biomedical discipline is the identification of the pathomechanisms of diseases and the integration of this knowledge into routine diagnosis and classification. Standard tools are macroscopic and microscopic analysis complemented by immunohistochemistry and molecular pathology. So far, classification has been based on the paradigm of cellular pathology established by Rudolf Virchow and others more than 150 years ago, stating that diseases originate from diseased cells. This dogma is meanwhile challenged by the fact that cells can be fully reprogrammed. Many diseases are nowadays considered to originate from undifferentiated stem cells, induced into a diseased state by genetic or epigenetic alterations. In addition, the completion of the Human Genome Project, with the identification of more than 20.000 genes and a much higher number of gene variants and mutations, led to the concept that diseases are dominated by genetics/epigenetics rather than cells of origin. The axiom of cellular pathology, however, still holds true, as cells are the smallest animate units from which diseases originate. Medical doctors and researchers nowadays have to deal with a tremendous amount of data. The International Classification of Diseases will expand from 14.400 entities/codes in ICD-10 to more than 55.000 in ICD-11. In addition, large datasets generated by “genomics“, e.g., whole-genome sequencing, expression profiling or methylome analysis, are meanwhile not only applied in research but also introduced into clinical settings. It constitutes a major task to incorporate all the data into routine medical work. Pathway pathology may help solve this problem. It is based on the realization that diseases are characterized by three essential components: (i) cells of origin/cellular context and (ii) the alteration of cellular as well as (iii) molecular/signal transduction pathways. The concept is illustrated by elaborating on two key cellular pathways, i.e., the cellular senescence of normal cells and the immortality of cancer cells, and by contrasting single cell/single pathway diseases, such as mycoplasma and coughing pneumonia, with complex diseases such as cancer, with multiple cell types as well as multiple affected cellular and signaling pathways. Importantly, the concept of pathway pathology is not just intended to classify disease, but also to conceive new treatment modalities. This article is dedicated to Dr. Leonard Hayflick, who made basic discoveries in pathway pathology not only by identifying cells causing disease (Mycoplasma pneumoniae) and establishing cell strains for treating disease (WI-38 for viral vaccines), but also by first describing cellular senescence and immortality.

Therapeutic Pathology- The Pathology of Tomorrow

“…The Pathology Pathway-popularly as it is called, intends to integrate genetic, molecular, and biological information into disease classification systems and treatment. Thus, making this huge amount of data available for medical doctors and scientists to grasp and apply for the benefit of individual patients [5]. This system has three fundamental components, i.e., (1) The cellular context of the disease;…”

Human Exome Sequencing and Prospects for Predictive Medicine: Analysis of International Data and Own Experience

“…Multifactorial diseases (MFDs) include almost all most prevalent chronic disorders, i.e., atherosclerosis, diabetes, obesity, bronchial asthma, osteoporosis, endometriosis, malignant tumors, and neuropsychiatric as well as cardiovascular diseases, arising from the interaction of many genes with adverse environmental factors [ 75 ]. Currently, the International Classification of Diseases (ICD) includes more than 55,000 nosological units [ 76 ]. The vast majority of them belong to MFDs.…”